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smir I. Syed, MD, Gabriel Maluenda, MD, Cedric Delhaye, MD, Nicholas Hanna, MD,
ohei Wakabayashi, MD, Kimberly Kaneshige, BS, William O. Suddath, MD,
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ashington, DC
bjectives We sought to examine the effect of insurance type upon the likelihood of receiving a
rug-eluting stent (DES).
ackground Recent guidelines suggest that consideration of a patient’s resources should play a
ole in decisions to use DES. Previous studies have also documented disparities in both access to
are and cardiovascular outcomes according to race, insurance, and socioeconomic status. The effect
f insurance status upon the decision to use DES is unclear.
ethods Patients undergoing percutaneous coronary intervention (PCI) with stenting from April
003 to June 2009, the so-called DES era, were retrospectively analyzed. Multivariable logistic regres-
ion was performed separately for patients 65 years and patients 65 years, with receipt of 1
ES during PCI as the outcome variable of interest. Insurance type was categorized as private, Medi-
are, Medicaid, and uninsured, based upon the primary insurance at discharge. Data regarding dura-
ion of clopidogrel therapy at 1 month, 6 months, and 1 year was also collected.
esults Among the 12,584 patients who underwent PCI with stenting, 6,157 (48.9%) had private
nsurance, 5,689 (45.2%) had Medicare, 467 (3.7%) had Medicaid, and 271 (2.2%) were uninsured at
he time of hospital discharge. There were no signiﬁcant differences by insurance type in duration
f dual antiplatelet therapy at 1 year. Both multivariable logistic regressions showed that Medicaid
atients (odds ratio [OR]: 0.60; 95% conﬁdence interval [CI]: 0.46 to 0.78 for age 65 years; OR: 0.45;
5% CI: 0.24 to 0.85 for age 65 years) and patients without insurance (OR: 0.57; 95% CI: 0.42 to
.78 for age 65 years; OR: 0.20; 95% CI: 0.05 to 0.86 for age 65 years) were less likely to receive DES.
onclusions Insurance status has a signiﬁcant impact upon the decision to use DES. Efforts to ad-
ress this disparity should focus on the patient-provider level. (J Am Coll Cardiol Intv 2010;3:
73–9) © 2010 by the American College of Cardiology Foundation
rom the Division of Cardiology, Washington Hospital Center, Washington, DC.anuscript received February 12, 2010; revised manuscript received April 7, 2010, accepted April 17, 2010.
D
s
t
i
b
(
r
h
o
s
a
f
(
t
(
s
a
s
a
(
i
d
i
h
r
M
S
f
w
I
a
r
2
s
d
p
v
m
p
e
m
h
h
A
m
d
w
u
c
I
i
A
p
m
a
C
a
I
c
m
d
c
t
6
o
c
n
S
t
o
r
w
a
A
a
A
o
i
c
f
S
m
a
w
w
w
A
a
C
b
C
D
M
O
P
c
S
e
i
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 3 , N O . 7 , 2 0 1 0
J U L Y 2 0 1 0 : 7 7 3 – 9
Gaglia et al.
Insurance Type and DES Use
774rug-eluting stents (DES), compared with bare-metal
tents, reduce in-stent restenosis and repeat revasculariza-
ion (1–5). Furthermore, data from both randomized clin-
cal trials and real-world registries indicate that DES are
oth safe and effective in a wide range of patients and lesions
6). Drug-eluting stents, however, also result in delayed
e-endothelialization and likely expose patients to a
igher risk for very late stent thrombosis, although
See page 780
verall rates of stent thrombosis are similar to bare-metal
tents (2,3,7). Therefore, recent guidelines recommend dual
ntiplatelet therapy (DAPT) with aspirin and clopidogrel
or at least 12 months in percutaneous coronary intervention
PCI) patients with DES (8,9). Because of the risk of stent
hrombosis associated with premature cessation of DAPT
10–13), the same guidelines also caution that a physician
hould not select DES for patients without access to or
unlikely to be compliant with
DAPT (8).
This decidedly vague recom-
mendation raises questions about
the impact of patient-level socio-
economic factors upon the deci-
sion to use DES. Although clini-
cal factors like the risk of bleeding
might be objectively assessed, the
impact of factors like type of in-
surance upon the clinical decision
to use DES is less easily quanti-
fied. There are also wide-ranging
published data documenting dis-
parities in access to care and out-
comes according to race, insur-
nce type, and socioeconomic status (14 –20). More
pecifically, African-American, poor, and uninsured patients
re less likely to be referred for invasive cardiac procedures
18,19,21). The influence of a patient’s insurance type upon
ndividual decisions to use DES, however, is less well-
ocumented. We therefore sought to examine the impact of
nsurance type upon the receipt of 1 DES during PCI,
ypothesizing that uninsured patients would be less likely to
eceive DES.
ethods
tudy population. Clinical, procedural, and follow-up data
or patients undergoing PCI with stenting at a single center
ere prospectively entered and retrospectively analyzed.
ndications for PCI included stable angina, unstable angina,
nd acute myocardial infarction (MI). This study was
estricted to patients receiving any stent between April 23,
bbreviations
nd Acronyms
ABG  coronary artery
ypass grafting
I  confidence interval
ES  drug-eluting stent(s)
I  myocardial infarction
R  odds ratio
CI  percutaneous
oronary intervention
TEMI  ST-segment
levation myocardial
nfarction003 and June 22, 2009, the so-called “DES era.” Stent telection was at the operator’s discretion and not dictated by
ifferences in cost or availability, because pricing of DES
latforms was approximately equal and contracts for indi-
idual DES were not in force. This database was then
erged with the hospital billing database, which includes
rimary insurance type (or lack thereof) and zip code for
ach patient at the time of hospital discharge. Zip code was
atched with U.S. Census Bureau data regarding median
ousehold income by zip code to approximate patient
ousehold income (22).
nticoagulation regimen. All patients received aspirin 325
g and clopidogrel 300 to 600 mg (at the operator’s
iscretion) before the procedure. Anticoagulation regimens
ere chosen at the operator’s discretion and included
nfractionated heparin targeted to achieve an activated
lotting time of 200 to 300 s, with or without a glycoprotein
Ib/IIIa inhibitor, or bivalirudin 0.75 mg/kg followed by an
nfusion of 1.75 mg/kg/h for the duration of the procedure.
fter the procedure, aspirin 81 to 325 mg daily was
rescribed indefinitely, and clopidogrel was prescribed for a
inimum of 1 month in patients receiving bare-metal stents
nd 6 months in patients receiving drug-eluting stents.
linical data and follow-up. The Institutional Review Board
t Washington Hospital Center and MedStar Research
nstitute (Washington, DC) approved this study. A dedi-
ated data coordinating center performed all data manage-
ent and analyses. Pre-specified clinical and laboratory data
uring hospital stay periods were obtained from hospital
harts reviewed by independent research personnel blinded
o the objectives of the study. Clinical follow-up at 30 days,
months, and 1 year was conducted by telephone contact or
ffice visits. Patients were asked if they were still taking
lopidogrel; if they had stopped taking clopidogrel, the total
umber of days on clopidogrel was recorded.
tudy deﬁnitions. Patients were placed in the DES group if
hey underwent PCI with 1 DES, for both on- and
ff-label indications. Primary insurance type was catego-
ized as private, Medicare, Medicaid, or uninsured. Race
as defined on the basis of the patient’s response upon
dmission. Patients identified themselves as African-
merican, Caucasian, Asian, Hispanic, or Native-American
nd could only select one. Patients were then defined as
frican-American or non–African-American for purposes
f comparison. Acute presentation was defined as present-
ng with unstable angina, non–ST-segment elevation myo-
ardial infarction, or ST-segment elevation myocardial in-
arction (STEMI).
tatistical analysis. Continuous variables are presented as
ean  SD; categorical variables are presented as percent-
ges. Differences in continuous variables between groups
ere compared with the Student t test. Categorical variables
ere compared with the chi-square test or Fisher exact test
hen appropriate. A p value 0.05 was considered statis-ically significant. To test the independent effect of insur-
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775nce type upon the likelihood of receiving 1 DES, we
onstructed 2 multivariable logistic regression models.
iven that all patients 65 years or older are eligible for
edicare, we performed separate multivariable logistic re-
ressions for patients 65 years of age and patients 65
ears of age. Private insurance was used as the reference
roup for both regressions. Covariables for both models
ere selected on the basis of significant univariable p values
nd overall clinical relevance, with particular attention to
linical factors that would make DES usage less likely.
ovariables for the multivariable models included insurance
ype, race, age, sex, current smoking status, baseline hemat-
crit, presentation with STEMI, presentation with shock,
nd a history of the following: PCI, coronary artery bypass
rafting (CABG), congestive heart failure (CHF), hyper-
ension, peripheral vascular disease, chronic renal insuffi-
iency (CRI), and diabetes mellitus. We tested for interac-
ion terms, including age and insurance, African-American
ace and insurance, and smoking and insurance; none of
hese terms was significant. Insurance type and median
ousehold income by zip code were collinear, although an
nteraction term between these 2 variables was not signifi-
ant; therefore median income was excluded from multiva-
iable analysis. Covariables in the models are expressed as
dds ratios (ORs) with 95% confidence intervals (CIs).
tatistical analyses were performed with SAS version 9.1
SAS Institute, Cary, North Carolina).
Table 1. Baseline Characteristics by Insurance Type
Variable
Private
(n  6,157)
Male 4,534 (73.7%)
Race
Caucasian 4,251 (69.0%)
African American 1,393 (22.6%)
Asian 204 (3.3%)
Hispanic 62 (1.0%)
Age 57.4 9.4
Median household income by zip code $62,680 20,821 $
STEMI 809 (14.8%)
NSTEMI or unstable angina 2,232 (40.8%)
Shock on presentation 189 (3.1%)
Previous coronary artery bypass surgery 787 (12.8%)
Previous percutaneous coronary intervention 1,356 (23.2%)
Congestive heart failure 517 (8.7%)
Diabetes mellitus 1,915 (31.3%)
Hypertension 5,120 (83.4%)
Hyperlipidemia 5,447 (88.9%)
Chronic renal insufﬁciency 436 (7.1%)
Peripheral vascular disease 567 (9.3%)
Baseline hematocrit 41.2 15.2
Current smoker 1,717 (27.9%)
Values presented as n (%) or mean SD.NSTEMI non–ST-segment elevation myocardial infarction; STEMI ST-segment elevation myocardialesults
aseline characteristics. This study included 12,584 patients
ho underwent PCI with stenting after April 25, 2003
Table 1). Six thousand one hundred fifty-seven (48.9%)
ad private insurance, 5,689 (45.2%) had Medicare, 467
3.7%) had Medicaid, and 271 (2.2%) were uninsured at the
ime of hospital discharge after PCI. Fifty-two percent of
atients were younger than 65 years of age; of this group,
,318 (81.3%) had private insurance, 576 (8.8%) had Medi-
are, 396 (6.1%) had Medicaid, and 254 (3.9%) were
ninsured. Eight thousand three hundred five (66.0%)
atients were Caucasian, 3,272 (26.0%) were African-
merican, 408 (3.2%) were Asian, 133 (1.1%) were His-
anic, and 47 (0.4%) were Native American. Patients with
edicare ($59,657), no insurance ($55,358), and Medicaid
$40,871) all had lower household median incomes than
atients with private insurance ($62,680; p  0.001 for
rend).
rocedural characteristics. Overall, 9,389 (74.6%) patients
eceived 1 DES. The proportion of patients by insurance
ype receiving 1 DES was 4,833 (78.5%) with private
nsurance, 4,111 (72.3%) with Medicare, 281 (60.2%) with
edicaid, and 164 (60.5%) without insurance (p  0.001
or trend). African Americans were less likely to receive
ES than non–African Americans (69.8% vs. 76.6%, p 
.001). Patients receiving DES, compared with patients not
icare
5,689)
Medicaid
(n  467)
Uninsured
(n  271) p Value
(57.8%) 249 (53.5%) 200 (73.8%) 0.001
(67.1%) 91 (19.5%) 143 (52.8%) 0.001
(25.9%) 314 (67.2%) 89 (32.8%) 0.001
(3.1%) 16 (3.4%) 14 (5.2%) 0.270
(0.8%) 15 (3.2%) 9 (3.3%) 0.001
 9.5 55.0 10.7 53.5 9.0 0.001
 20,908 $40,871 15,597 $55,358 16,412 0.001
(10.9%) 113 (25.5%) 84 (33.5%) 0.001
(37.2%) 148 (33.3%) 71 (28.3%) 0.001
(4.2%) 34 (7.4%) 19 (7.1%) 0.001
(23.8%) 59 (12.7%) 20 (7.4%) 0.001
(26.1%) 98 (23.0%) 43 (16.7%) 0.001
(20.4%) 82 (18.1%) 32 (12.2%) 0.001
(38.6%) 205 (44.4%) 75 (27.9%) 0.001
(90.8%) 412 (88.4%) 203 (75.2%) 0.001
(89.7%) 392 (84.7%) 208 (77.6%) 0.001
(20.6%) 81 (17.6%) 10 (3.7%) 0.001
(21.6%) 59 (12.9%) 12 (4.4%) 0.001
 10.7 39.2 5.1 42.5 25.1 0.001
(13.8%) 234 (50.1%) 157 (57.9%) 0.001Med
(n 
3,284
3,820
1,476
174
47
73.2
59,657
556
1,905
234
1,345
1,342
1,124
2,177
5,146
5,052
1,165
1,215
38.6
787infarction.
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776eceiving DES, were less likely to present with STEMI or in
hock, more likely to have undergone PCI in the past, and
ess likely to have a history of CRI, CHF, and smoking
p  0.001 for all comparisons). There was a trend for
atients receiving DES to be younger (62.6 vs. 64.7 years,
 0.06).
Patients with Medicare were more likely to have PCI of
he left main (2.5% vs. 1.5% overall) or of a saphenous vein
raft (6.2% vs. 4.5% overall). Stented length (19.8  6.7
m overall) and procedural success (98.1% overall) were
imilar in all 4 insurance groups. Patients with Medicaid or
ithout insurance, compared to patients with private insur-
nce, were more likely to receive a glycoprotein IIb/IIIa
nhibitor and less likely to receive bivalirudin or have
ntravascular ultrasound used.
uration of clopidogrel. We collected data regarding the
ength of clopidogrel therapy for 6,420 patients at 1 month,
,829 patients at 6 months, and 4,731 patients at 1 year after
CI (Table 2). This amounted to clopidogrel data available
or 52% of patients alive at 1 month, 48% alive at 6 months,
nd 39% alive at 1 year after PCI. When analyzed by
nsurance type, there were no significant differences between
Table 2. Patients Still Taking Clopidogrel by Insurance Status and Receipt
1 Month
DES No DES
p Value
(Row) DE
Private (n  6,157) 2,881/2,904 (99.2%) 334/336 (99.4%) 1.0 2,561/2,66
Medicare (n  5,689) 2,526/2,555 (98.9%) 357/363 (98.4%) 0.43 2,181/2,33
Medicaid (n  467) 146/149 (98.0%) 24/25 (96.0%) 0.47 137/14
Uninsured (n  271) 80/80 (100%) 8/8 (100%) — 64/7
Percentage values represent the proportion of patients with a specific type of insurance and type o
DES drug-eluting stent(s).
Table 3. Adjusted Odds Ratios for Receipt of at Least 1 DES
Variable
Age <65 yrs
Odds Ratio 95% CI
Uninsured 0.57 0.42–0.78
Medicaid 0.60 0.46–0.78
Medicare 0.83 0.64–1.06
African-American 0.80 0.68–0.93
Age (per 10 yrs) 1.08 1.00–1.17
Male 0.71 0.60–0.84
Current smoker 0.80 0.69–0.93
Baseline hematocrit (per 5%) 1.18 1.10–1.26
STEMI 0.41 0.34–0.49
Shock 0.40 0.29–0.55
HTN 0.75 0.62–0.92
CHF 0.88 0.70–1.11CHF history of congestive heart failure; CI confidence interval; HTN history of hypertension; Shockhe DES and no DES groups regarding the length of
lopidogrel therapy.
ultivariable analysis. Results of the 2 multivariable logistic
egressions were similar, showing that patients with Med-
caid (OR: 0.60; 95% CI: 0.46 to 0.78 for age 65 years;
R: 0.45; 95% CI: 0.24 to 0.85 for age 65 years) and
atients without insurance (OR: 0.57; 95% CI: 0.42 to 0.78
or age 65 years; OR: 0.20; 95% CI: 0.05 to 0.86 for age
65 years) (Table 3) were less likely to receive DES than
atients with private insurance. African Americans, compared
ith non–African Americans, were also less likely to receive
ES (OR: 0.80; 95% CI: 0.68 to 0.93 for age65 years; OR:
.77; 95% CI: 0.65 to 0.90 for age 65 years). DES use was
lso less likely in patients with STEMI, shock, male sex,
urrent smoking history, lower baseline hematocrit, and
istory of hypertension. A history of CABG, CRI, diabetes
ellitus, and peripheral vascular disease were not significant
fter multivariable adjustment.
There were some differences between the multivariable
ogistic regressions for patients 65 and 65 years. Specif-
cally, older age increased the likelihood for receipt of DES
n the younger cohort but had the opposite effect in the
Least 1 DES
6 Months 1 Yr
No DES
p Value
(Row) DES No DES
p Value
(Row)
%) 261/291 (89.7%) 0.001 1,990/2,188 (91.0%) 177/202 (87.6%) 0.12
%) 265/298 (88.9%) 0.005 1,678/1,925 (87.2%) 183/212 (86.3%) 0.73
%) 20/21 (95.2%) 0.51 113/121 (93.4%) 15/17 (88.2%) 0.36
%) 8/8 (100%) 1.0 52/59 (88.1%) 7/7 (100%) 1.00
till taking clopidogrel; p values apply only to the specified time period.
Age >65 yrs
p Value Odds Ratio 95% CI p Value
0.0004 0.20 0.05–0.86 0.03
0.0001 0.45 0.24–0.85 0.01
0.14 0.89 0.72–1.09 0.25
0.004 0.77 0.65–0.90 0.0008
0.05 0.76 0.68–0.85 0.0001
0.0001 0.83 0.71–0.96 0.01
0.003 0.73 0.59–0.89 0.003
0.0001 1.10 1.03–1.18 0.008
0.0001 0.44 0.36–0.55 0.0001
0.0001 0.32 0.23–0.46 0.0001
0.005 0.75 0.58–0.96 0.02
0.27 0.83 0.70–0.99 0.04of at
S
5 (96.1
5 (93.4
1 (97.2
0 (91.4
f stent spresented with shock; STEMI presented with STEMI; other abbreviation as in Table 2.
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777lder cohort. In addition, history of CHF slightly decreased
he likelihood for receipt of DES in the older cohort; this
ffect in the younger cohort, however, was not significant.
ost importantly, however, Medicaid, no insurance, and
frican-American race were associated with less use of DES
n both models; Medicare was not.
iscussion
e found that patients with Medicaid or no health insur-
nce were less likely to receive DES than patients with
rivate insurance. We also found that African-American
atients were less likely to receive DES than non–African-
merican patients. These differences remained significant
fter multivariable adjustment. Our results suggest that
nsurance status and race influence the decision to use DES.
Numerous studies have shown that the uninsured and
atients with Medicaid suffer worse cardiovascular outcomes,
re less likely to receive evidence-based therapies for acute
oronary syndromes, are less likely to be referred for coronary
ngiography and for revascularization (14,16,23–26). Robust
ublished data also document that African-American patients
ave worse cardiovascular outcomes and are less likely to be
eferred for cardiac catheterization, PCI, CABG, and defibril-
ator implantation (19–21,27,28). Previous studies have docu-
ented similar disparities regarding use of DES, with some
aveats. An analysis of the CRUSADE (Can Rapid Risk
tratification of Unstable Angina Patients Suppress Adverse
utcomes with Early Implementation of the ACC/AHA
uidelines) multicenter registry in 2005 showed that patients
ith Medicaid—but not Medicare or without insurance—
ere less likely to receive DES than patients with private
nsurance (28). A similar analysis of the National Cardiovas-
ular Data Registry in 2006 found that lack of insurance
educed the likelihood of receiving a DES, as did African-
merican race (29). And another study of this national registry
n 2008 showed that government insurance and lack of
nsurance were associated with less use of DES (30). The use
f 1 DES varied widely in these studies, from 55% to 96%;
n our study this prevalence was 75%.
This disparity in receipt of DES is unique in that it arises
fter the referral for catheterization, when the barrier of
ccess to care has been removed. This implies that its
enesis might be at the patient-provider level. We found
hat, even if one assumes that a patient without insurance is
ess likely or able to take clopidogrel for an extended period,
atients with Medicaid were also less likely to receive DES.
he reasons for this are obscure.
Recent guidelines specify “ . . . in patients not expected to
omply with 12 months of thienopyridine therapy, whether
or economic or other reasons, strong consideration should
e given to avoiding a DES . . . ” (9). Patients not expected
o comply, however, are not further defined. In the
REMIER registry (Prospective Registry Evaluating Myo- gardial Infarction: Events and Recovery), older age, less than
high school education, unmarried status, a lack of dis-
harge instructions regarding clopidogrel, and avoiding
ealth care because of cost were associated with premature
essation of clopidogrel in DES-treated patients (13). Our
tudy found that duration of clopidogrel therapy (up to 1
ear) was more or less similar in different insurance groups,
egardless of DES status. These data almost certainly bias
oward higher rates of compliance with clopidogrel therapy
t 1 year, because patients without adequate follow-up are
ore likely to stop clopidogrel or not receive a DES in the
rst place. In addition, our clopidogrel data only account for
pproximately one-half of the patients in the present study.
evertheless, these data are at the very least hypothesis-
enerating and suggest that patients’ capacities and re-
ources to take clopidogrel for an extended period of time
ight be underestimated by physicians.
The cost to the patient for clopidogrel therapy might also
lay a role in decisions to use DES. The out-of-pocket cost
or a 1-month supply of clopidogrel, for example, can be as
igh as $150. Although we do not have patient-level data
egarding prescription costs, the copayment for Medicaid
atients in the area of this study (District of Columbia,
aryland, Virginia) is typically $1 to $3 per month. This is
n contrast to the cost of Medicare copayments (for patients
ith Medicare prescription coverage), which ranges from
20 to $80/month. Therefore, the high out-of-pocket cost
or patients without insurance might influence individual
ecisions to use DES, but this factor alone is inadequate to
xplain the disparity in patients with Medicaid (or the
bsence of a disparity in patients with Medicare).
There is a paucity of published data regarding the identifi-
ation of patients more or less likely to comply with clopi-
ogrel. Some evidence suggests that African Americans are less
illing than Caucasians to undergo PCI or CABG (31).
imilar research focused upon beliefs and attitudes toward
ES and thienopyridine therapy, and accompanying physician
erception of the capacity to take prolonged thienopyridine
herapy, is sorely lacking. It is also unclear what role physician
eimbursement for DES or lack thereof plays in this equation.
Our analysis is unique in that all patients were referred for
CI at a single center, unlike previous analyses of disparities
n DES use. It is also in a high-volume setting, which
liminates the impact of hospital-level characteristics that
nfluenced the use of DES in previous studies (29). We were
lso able to study the use of DES in a “real-world” setting,
n a racially and socioeconomically diverse cohort of pa-
ients, for both on- and off-label indications. Nevertheless,
iven the retrospective nature of our analysis, it is prone to
ifficulties common to all nonrandomized studies. Specifi-
ally, there might be confounding variables not accounted
or by the final logistic regression model for receipt of DES.
n addition, propensity score matching was not practical,
iven the 4 insurance subgroups of differing sizes. We were
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778nable to assess the impact of median household income by
ip code upon the receipt of DES, because of collinearity
etween insurance status and median household income by
ip code; an interaction term between income and insurance
tatus, however, was not significant. Furthermore, previous
tudies have shown that increasing income does not signif-
cantly attenuate the impact of insurance status upon health
utcomes (32). In addition, we did not have access to
articularly detailed income data; our use of median income
y zip code might result in misclassification of actual income
33,34). Also, race was self-reported but coded as mutually
xclusive categories. Federal guidelines specify self-
eporting of race as the preferred method but recognize race
e.g., African-American, Caucasian) and ethnicity (e.g.,
ispanic or non-Hispanic) as separate categories and ac-
nowledge that individuals might identify with 1 race
35). Lastly, we defined insurance status on the basis of the
rimary coverage at discharge. Given that patients might
e uninsured at the time of PCI and then receive insurance
overage during their hospital stay, we likely underestimated
he number of uninsured at the time of PCI.
onclusions
his analysis does not presume that DES are a panacea for
mprovement in cardiovascular outcomes. Nevertheless, rec-
gnition of this disparity in use and a more nuanced
nderstanding of factors at the patient-provider level that
ontribute to this disparity would undoubtedly lead to less
arget vessel revascularization in underserved and minority
opulations.
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